9-12 June 2021 Digital Conference
EPS2-001 | Drug-induced liver injury from antibiotics administered to adult cystic fibrosis patients: is it a problem? A single-centre retrospective study | Rachael Meredith | Received |
EPS3-001 | Is variation in Pseudomonas aeruginosa (Pa) surface-enhanced Raman spectroscopy (SERS) spectra related to phenotype? | Danielle Allen | Received |
EPS1-001 | Physiotherapy practice of French cystic fibrosis children changed during lockdown due to COVID-19 pandemic | Marie Mittaine | Received |
P-001 | TCR repertoire in monozygotic cystic fibrosis twins | Burkhard Tmmler | Received |
P-002 | Genetic characteristics of the cystic fibrosis Polish patients registered in the public Matio Polish Cystic Fibrosis Foundation | Karolina Surma | Received |
EPS3-002 | Using rapid evaporative ionisation mass spectrometry (REIMS) for biomarker discovery and mechanistic studies of Pseudomonas aeruginosa stress responses | Rob Bradley | Received |
EPS1-002 | The impact of COVID-19 on the prescribing practice of specialist cystic fibrosis physiotherapist non-medical prescribers in the UK | Catherine Brown | Received |
EPS3-003 | Using airway organoids and Air Liquid Interface cultures to profile the spatial and temporal dynamics of Pseudomonas aeruginosa infections | Signe Lolle | Received |
EPS1-003 | Recommended shielding against COVID-19 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis | Elpis Hatziagorou | Received |
EPS2-003 | Lumacaftor-ivacaftor therapy and its impact on glucose tolerance in children with cystic fibrosis | Kathy McGrath | Received |
EPS3-004 | Depolarisation of the Pseudomonas aeruginosacytoplasmic membrane by Glatiramer acetate potentiates the antibacterial activity of tobramycin | Ronan Murphy | Received |
EPS1-004 | Audit of virtual exercise class during COVID-19 in children with cystic fibrosis | Zoe Johnstone | Received |
EPS2-004 | The role of Flash Glucose Monitoring System at annual review during the COVID-19 restrictions, within Cystic Fibrosis Diabetes Service at Blackpool Adult Cystic Fibrosis Centre. UK | Julie Knowles | Received |
EPS2-005 | Arm circumference and skinfolds vs. body mass index: a single-centre experience over two decades | Dorothea Appelt | Received |
EPS1-005 | Evaluating impacts of the change from clinic to home spirometry on clinicians and adults with cystic fibrosis | Tracey Daniels | Received |
P-005 | Mild variants of the CFTR gene in Russian patients without clinical manifestations | Yuliya Melyanovskaya | Received |
P-006 | The complex allele c.1399CT;1521_1523delCTT (L467F;F508del) of the CFTR gene in Russian cystic fibrosis patients | Nataliya Kashirskaya | Received |
EPS3-006 | Low induction of Antibiotic resistance by two new drugs against Pseudomonas aeruginosa in a clinical cohort of cystic fibrosis patients | Mette Kolpen | Received |
EPS2-006 | What do people with cystic fibrosis eat? Diet quality, macronutrient and micronutrient intakes compared to recommended guidelines in adults with cystic fibrosis: a systematic literature review | Nicola Drummond | Received |
EPS1-006 | A retrospective audit of home-based spirometry quality in a large UK adult cystic fibrosis centre | Ian Waller | Received |
P-007 | A novel cystic fibrosis-causing mutation identified in a newborn of African origin | Natalia Cirilli | Received |
EPS1-007 | Impact of COVID-19 on cystic fibrosis physiotherapy outpatient clinics | Emily Scott | Received |
EPS2-007 | How did the COVID-19 lockdown influence the nutritional status and body composition of cystic fibrosis patients in Poland? | Monika Mielus | Received |
EPS3-007 | Predictors of eradication failure at first isolation of MRSA in children with cystic fibrosis | Almala Pinar Ergenekon | Received |
EPS2-008 | The model for determining risk groups for the development of vitamin D deficiency and prevention algorithm in children with cystic fibrosis using the multifactor dimensionality reduction method | Elena Zhekaite | Received |
P-008 | Identification of two novel mutations (c.3639dup and ex16-17a dup) in the CFTR gene in Polish patient with cystic fibrosis | Sebastian Wardak | Received |
EPS3-008 | Evaluation of a fixed-step eradication regime in children with cystic fibrosis and detection of Pseudomonas aeruginosa | Simon Florian Grewendorf | Received |
EPS1-008 | Exercising online a Beaming good initiative | Gemma McCrea | Received |
EPS3-009 | Biofilm formation in methicillin-resistant Staphylococcus aureus isolated in cystic fibrosis patients is strain-dependent and differentially influenced by antibiotics | Agathe Boudet | Received |
P-009 | The investigation of the effect of electrolyte disorder on sweat test in newborns with positive cystic fibrosis screening test | Sevgi Pekcan | Received |
EPS2-009 | F508del genotype is an independent risk factor for reduced bone mineral density in children with cystic fibrosis | JASNA RODMAN BERLOT | Received |
EPS1-009 | Adapting services during the COVID-19 pandemic a patient evaluation of physiotherapy telephone reviews within multidisciplinary team virtual clinics | Sarah Fitzgerald | Received |
P-010 | Newborn screening for cystic fibrosis improves nutritional outcome: monocentric data of the first 4 years in Germany | Katharina Schtz | Received |
EPS2-010 | Pregnancy and cystic fibrosis: patients experience from pre-conception to birth | Marilyn Hagan | Received |
EPS3-010 | Clinical pharmacokinetics and dose recommendations for posaconazole gastro-resistant tablets in children with cystic fibrosis | Sian Bentley | Received |
P-011 | Cystic fibrosis - newborn screening (CF-NBS) start-up in Flanders (Belgium): report of first evaluation after two years | Marijke Proesmans | Received |
P-012 | Two years neonatal screening for cystic fibrosis in Republic of North Macedonia | Stojka Fustik | Received |
P-013 | Evaluation of improvements of the cystic fibrosis newborn screening protocol in the Netherlands | Marelle Bouva | Received |
P-015 | Evaluation of the specificity and sensitivity of the cut-off values of immunoreactive trypsinogen in the cystic fibrosis newborn screening program | Tugba Ramasli Gursoy | Received |
P-016 | The role of clinical and laboratory findings in the diagnosis of cystic fibrosisin children with positive newborn screening | Tugba Ramasli Gursoy | Received |
P-017 | Different ethnical distribution of the incidence of cystic fibrosis in Republic of North Macedonia | Violeta Anastasovska | Received |
P-018 | Follow-up of children with Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) in Switzerland | Orell Imahorn | Received |
P-019 | Inconclusive Cystic Fibrosis Positive Neonatal Screening (CFSPID): clinical outcomes | Silvia Gartner | Received |
P-020 | CFTR mutation panel in detecting cystic fibrosis screen positive inconclusive diagnosis patients (CFSPIDs) in the Marche Region, Italy | Natalia Cirilli | Received |
P-021 | An evaluation of the cystic fibrosis newborn screening service at Royal Manchester Childrens Hospital - experience from a tertiary service provider in Northwest United Kingdom | Anirban Maitra | Received |
P-022 | Evaluation of hearing and vestibular system in patients with cystic fibrosis | Beste zsezen | Received |
P-023 | Characterisation of CFTR function in a patient with the F508del/CFTRdup1-3 genotype | Senne Cuyx | Received |
P-024 | Pili annulati: is it a new finding in cystic fibrosis? | SEVG&304; PEKCAN | Received |
P-025 | Systems biology modelling of CFTR maturation to predict possible active compound combinations | Liza Vinhoven | Received |
P-026 | Characterisation of F508del-CFTR rescue by corrector MCG1516A | Mafalda Bacalhau | Received |
P-027 | Identification of corrector combinations to increase the rescue of F508del-CFTR traffic and function | Filipa Castela Ferreira | Received |
P-028 | Identification of novel F508del-CFTR correctors among triazole derivative compounds | Mafalda Bacalhau | Received |
P-029 | First report: Kaftriovs. Symkeviin intestinal organoids | Eva Furstova | Received |
P-030 | Metabolomic impact of the restoration of CFTR activity in the respiratory epithelium | Emmanuelle Bardin | Received |
P-031 | The last 10: small molecule screening for correctors of rare CFTR processing mutations | Marjolein Ensinck | Received |
P-032 | Chemical optimisation of a PI3Ky competing peptide for the therapy of cystic fibrosis | Angela Della Sala | Received |
P-033 | Therapeutic approach by translational suppression of non-sens mutation in CFTR gene | Sabrina Karri | Received |
P-034 | Novel insights into the therapeutic potential of antisense oligonucleotides as splicing modulators in respiratory and intestinal patient-derived model systems | Noemie Stanleigh | Received |
P-035 | iPSC-derived macrophages from cystic fibrosis patients as a cell source to establish in vitro infection models and a drug screening platform | Claudio Rodríguez-González | Received |
P-036 | Analysis of the dysfunction of cystic fibrosis macrophages | Claudio Rodríguez-González | Received |
P-037 | Elexacaftor/tezacaftor/ivacaftor improve lung disease in patients with advanced cystic fibrosis homozygous for the F508del mutation | Donatello Salvatore | Received |
P-038 | An Italian centre experience with elexacaftor-tezacaftor-ivacaftor therapy in cystic fibrosis patients with advanced lung disease | Chiara Rosazza | Received |
P-039 | The clinical impact of triple CFTR modulator therapy in a cohort of people with CF and severe lung disease | Orla Fanthorpe | Received |
P-040 | Compassionate use triple therapy CFTR modulation (Kaftrio) in severe disease. Single-centre, real-world clinical outcomes, safety and tolerability | David Morrissy | Received |
P-041 | Effect of thetriplecombination of CFTR correctors and potentiatoron lung function, BMI and the Brasfield score in adolescents with cystic fibrosis | Marina Praprotnik | Received |
P-042 | RECOVER - the Real World Clinical Outcomes with Novel Modulator therapy combinations in people with cystic fibrosis | Paul McNally | Received |
P-043 | A snapshot of respiratory microbiology results pre- and post-commencing Kaftrio | Laura Jenkins | Received |
P-045 | Are people with cystic fibrosis reducing their medication since Kaftrio initiation? | Michael Dooney | Received |
P-046 | Menstrual abnormalities linked to Kaftrio | Michael Dooney | Received |
P-047 | Impact of tezacaftor/ivacaftor/elexacaftor on outcome in a patient with I336Kmutation and a minimal function mutation R553X | Sivagurunathan Sutharsan | Received |
P-048 | Olfactory dysfunction: impact of highly effective modulator therapy | Daniel Beswick | Received |
P-049 | Tolerance induction (hyposensitisation) in drug intolerance to CFTR modulators | Patience Eschenhagen | Received |
P-050 | Drug desensitisation for lumacaftor/ivacaftor - step-by-step to drug tolerance | Julia Westhoff | Received |
P-051 | Rollout of Kaftrio to adult cystic fibrosis patients at the Royal Brompton Hospital during a global pandemic | Elaine Bowman | Received |
P-052 | Managing the roll out of the cystic fibrosis modulator therapy Kaftrio at a large UK adult centre | Constance (Connie) Takawira | Received |
P-053 | Real-life clinical effects of therapy with lumacaftor and ivacaftor in patients with cystic fibrosis | Isabella Comello | Received |
P-054 | Clinical outcomes in people with cystic fibrosis treated with lumacaftor/ivacaftor in routine clinical practice in Sweden | Anders Lindblad | Received |
P-056 | Intestinal current measurement (ICM) in cystic fibrosis paediatric patients - a pilot study | Magdalena Postek | Received |
P-057 | Cystic fibrosis children not eligible for modulators therapy - data from a tertiary paediatric centre in Northwest United Kingdom | Ghulam Mujtaba | Received |
P-058 | The effect of hypertonic saline treatment in preschoolers with cystic fibrosis on lung structure as measured by chest computed tomography (CT). SHIP-CT study: feasibility of CT scan protocol | Harm A.W.M. Tiddens | Received |
P-059 | A double-blind randomised multicentre European study of linoleic acid supplementation for one year in patients with cystic fibrosis | Birgitta Strandvik | Received |
P-060 | Phage therapy for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients | Maya Kahan-Hanum | Received |
P-061 | The UK Clinical Trials Accelerator Platform - a national cystic fibrosis clinical trials network increasing access to clinical trials for the UK cystic fibrosis community | Rebecca Brendell | Received |
P-062 | Impact of the SARS-CoV-2 pandemic on clinical trials in the ECFS-CTN during 2020 | Fiona Dunlevy | Received |
P-063 | Community involvement in shaping cystic fibrosis clinical trials | Lorna Allen | Received |
P-064 | How does early weight gain explain the effect of childhood socioeconomic conditions on lung function for children with cystic fibrosis? A UK Registry-based study | Daniela Schlter | Received |
P-066 | Lung function and pulmonary exacerbations among individuals with cystic fibrosis living near composting facilities in the United Kingdom | Muhammad Saleem Khan | Received |
P-067 | Mechanisms for the effect of CFRD on mortality: a causal mediation analysis using UK cystic fibrosis Registry data | Kamaryn Tanner | Received |
P-068 | Estimating the long-term effects of insulin on outcomes in cystic fibrosis-related diabetes: a target trial approach | Emily Granger | Received |
P-069 | Cystic fibrosis-related liver disease a decade of experience | Ana Mocic Pavic | Received |
P-070 | Epidemiology of nontuberculous mycobacteria in a single adult cystic fibrosis centre | Ayesha Kumar | Received |
P-071 | Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centres perspective | Anina Ratjen | Received |
P-072 | Psychometric validation of the Cystic Fibrosis Impact Questionnaire: a patient-reported outcome instrument assessing the life impacts of cystic fibrosis | Daniel Serrano | Received |
P-073 | Influence of assessment tool and publication type on the reported prevalence of depression and anxiety in adults with cystic fibrosis: a meta-analysis | Louise Lord | Received |
P-074 | Setting up a framework for the collection of patient-reported outcomes in the real world: trials and tribulations | Elise Lammertyn | Received |
P-075 | Are there lessons to be learned from cystic fibrosis patient deaths and the timing of lung transplant referral? | Kavita Dave | Received |
P-076 | Using the Cystic Fibrosis Foundation consensus guidelines to assess the timing of lung transplant referral for individuals with cystic fibrosis in a single large adult UK centre: do they help? | Kavita Dave | Received |
P-077 | Clinical factors affecting timing of referral for lung transplantation for people with cystic fibrosis: a national comparison of opinions between adult cystic fibrosis and transplant centres | Kavita Dave | Received |
P-078 | The burden of cystic fibrosis beyond medical costs in Switzerland | Christina Tzogiou | Received |
P-079 | Using a learning health system to understand medicine waste in cystic fibrosis the Easy Medicines for Burden Reduction And Care Enhancement (EMBRACE) study | Amanda Bevan | Received |
P-081 | 30 years of organisation of care for cystic fibrosis patients in the Russian Federation | Yuliya Melyanovskaya | Received |
P-082 | The National Cystic Fibrosis Patient Registry of the Russian Federation 9 years of experience (2011-2019) | Nataliya Kashirskaya | Received |
P-083 | Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study | Elliot McClenaghan | Received |
P-084 | The impact of the SARS-CoV-2 pandemic on people living with cystic fibrosis in Ireland: real-world data from the Irish cystic fibrosis registry | Huw Rees | Received |
P-085 | Impact of COVID-19 on hospital services and specialist care of adults with cystic fibrosis | Rini Bhatnagar | Received |
P-086 | The impact of COVID-19 in people with cystic fibrosis a single-centre experience | Georgina Aldous | Received |
P-087 | Impact of COVID-19 on mental health of children with cystic fibrosis and their parents | Rini Bhatnagar | Received |
P-088 | Impact of COVID-19 and cocooning on employment of people with cystic fibrosis | Rini Bhatnagar | Received |
P-089 | Coronavirus infection (COVID 19) in children with cystic fibrosis of the Russian Federation | Yuliya Melyanovskaya | Received |
P-090 | A UK survey on changes in managing people with cystic fibrosis during the COVID-19 pandemic | Saffana Hameed | Received |
P-091 | Regularity of check-ups at the cystic fibrosis centre in the time of COVID-19 pandemic | Ivana Todori&263; | Received |
P-092 | Embedding an electronic patient record into a developing UK service and impact during the COVID-19 pandemic - Blackpool Adult Cystic Fibrosis Service (BACFS) | Natasha Pickering | Received |
P-094 | Facilitating cystic fibrosis research during the COVID-19 pandemic | Sharon Burnett | Received |
P-095 | Effect of age and genotype on lung function in children with cystic fibrosis | Shadrina Vera | Received |
P-096 | Long-term follow-up of adolescent and adult patients with cystic fibrosis: a single centres experience | Asl&305; &304;mran Y&305;lmaz | Received |
P-097 | Whos talking about cystic fibrosis? The changing landscape of internet postings related to cystic fibrosis: a two-year comparative study | Tamara Vagg | Received |
P-098 | Change in FEV1 after standardised care algorithm for cystic fibrosis patients: quality improvement project | Muruvvet Cenk | Received |
P-100 | Quality of home spirometry performance amongst adults with cystic fibrosis | Jody Bell | Received |
P-101 | Provision of home spirometry in a physiologist-led service: experiences from a large adult cystic fibrosis centre | Scott Hawkes | Received |
P-102 | Utility of Dynamic Chest Radiography (DCR) for calculating lung volume subdivisions in adult people with cystic fibrosis | Thomas Simon FitzMaurice | Received |
P-103 | Longitudinal SF6 multiple breath washout testing in children aged 0-4 years with cystic fibrosis | Rikke Sandvik | Received |
P-104 | Multiple-breath nitrogen washout test and structural lung damage in adult patients with cystic fibrosis | Alexander Cherniak | Received |
P-105 | Lung clearance index in monitoring response to antibiotic therapy in children with cystic fibrosis | Katarzyna Walicka-Serzysko | Received |
P-106 | Positioning may not affect lung clearance index | TJ BAKER | Received |
P-107 | Lung clearance index in Bulgarian patients with cystic fibrosis | Boryana Gospodinova | Received |
P-108 | Cross-sectional and longitudinal comparison of N2 and SF6 multiple breath washout in children with cystic fibrosis aged 2-45 months | Rikke Sandvik | Received |
P-109 | Regional assessment of lung function using non-contrast MRI in people with cystic fibrosis | Jonathan Brooke | Received |
P-110 | A soft, flexible, wearable device for cough detection in paediatric cystic fibrosis patients | Andreas Tzavelis | Received |
P-111 | CT-signs and the effectiveness of surgical treatment of sinonasal disease in children with cystic fibrosis | Yulia Gorinova | Received |
P-112 | Sleep disorders and exercise capacity in adult patients with cystic fibrosis in the Republic of North Macedonia | Tatjana Jakovska Maretti | Received |
P-113 | Integration of Qi Gong sessions into a respiratory rehabilitation program: the experience of the CF Centre in Roscoff (France) | Laetitia Gueganton | Received |
P-114 | Neutrophil effector responses to cystic fibrosis clinical isolates of Pseudomonas aeruginosa | Kayla Fantone | Received |
P-115 | Effectiveness of different eradication treatment protocols for the first Pseudomonas aeruginosa isolation in paediatric cystic fibrosis patients | Birce Sunman | Received |
P-116 | Clinical characteristics of frequent and infrequent pulmonary exacerbations of cystic fibrosis lung disease | Claire Houston | Received |
P-118 | Lung ultrasound in cystic fibrosis exacerbations | Ioana Ciuca | Received |
P-119 | Improving Home IV outcomes | Christina Ryan | Received |
P-120 | Bridging the gap enhancing a multidisciplinary team Home IV service to reduce discrepancy in cystic fibrosis care | Victoria Kendall | Received |
P-121 | The effect of training about nebuliser cleaning and disinfection on the knowledge levels and practises of the caregivers of patients with cystic fibrosis | Muruvvet Cenk | Received |
P-122 | The role of the clinical pharmacy specialist in monitoring adherence to inhaled therapies in patients with cystic fibrosis in the Republic of North Macedonia | Marija Atanasova Nadzinska | Received |
P-123 | Adaptive immune response to Mycobacterium abscessus complex and cross-reactivity of BCG vaccination | Renan Mauch | Received |
P-124 | Implementing an anti-emetic protocol improves morbidity associated with intravenous therapy for Mycobacterium abscessus in children | Anupama Menon | Received |
P-125 | Impact of infection withAchromobacterspp.on clinical outcome in paediatric patients with cystic fibrosis | Birce Sunman | Received |
P-127 | Pulsed intravenous methylprednisolone for allergic bronchopulmonary aspergillosis in cystic fibrosis | Tamsin Thornton | Received |
P-128 | A review of inhaled corticosteroid prescribing in an adult cystic fibrosis population | Claire McKeown | Received |
P-129 | Induced sputum as a minimally invasive sample to investigate airway inflammation in the early course of cystic fibrosis | Vincent Giacalone | Received |
P-130 | Chronic inflammation biomarkers and lung function in cystic fibrosis patients | Mihaela Dediu | Received |
P-132 | The Induced Immune response in CF patients | Mads Lausen | Received |
P-133 | Impact of specialised pro-resolving lipid mediators on cystic fibrosis airway epithelial cell functions | Malle Briottet | Received |
P-134 | SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multicentre prospective study with a control group | Carla Colombo | Received |
P-136 | Relationship between cystic fibrosis disease severity and susceptibility to COVID-19 infection | MERVE ATALAY | Received |
P-137 | COVID-19 in cystic fibrosis patients with and without lung transplantation: the Zurich cohort | Carolin Steinack | Received |
P-139 | Evaluating the impact of a telemedicine service during the COVID-19 pandemic in people with cystic fibrosis | Alex Bull | Received |
P-140 | TeCC (TeleMedicine, Cystic Fibrosis, Corona-Virus) study in a previous telemedicine-naive centre: clinical challenges, outcomes, and user experience in the first six months of a global pandemic | David Morrissy | Received |
P-142 | Lung and gut microbiota signatures in cystic fibrosis mice challenged with Pseudomonas aeruginosa | Annamaria Bevivino | Received |
P-145 | Unwanted effects of an essential oil component, citral, on the susceptibility of Pseudomonas aeruginosato antibiotics | Alexandre Tetard | Received |
P-146 | Intra-patient evolution of a pulmonary strain of Pseudomonas aeruginosa,from primocolonisation until after lung transplant | Susie Gaillot | Received |
P-148 | Different treatment regimens in first isolation of Pseudomonas aeruginosa | Cansu Yilmaz Yegit | Received |
P-149 | Evolution of levofloxacin resistance and phenotypic characterisation of Pseudomonas aeruginosaclinical isolates from people with cystic fibrosis | Callum Sloan | Received |
P-150 | Competitive fitness experiments of CF isolates of Pseudomonas aeruginosa in human and murine precision-cut lung slices (PCLS) | Lion Wege | Received |
P-151 | Improved isolation yields for bacteriophage active against Staphylococcus aureus | Joshua Iszatt | Received |
P-152 | Clinical findings and long-term effect of methicillin-resistant Staphylococcus aureus isolation in patients with cystic fibrosis | Beste Ozsezen | Received |
P-153 | Exophiala dermatitidis infection in cystic fibrosis patients accelerates lung function decline: a retrospective single-centre review of historical lung function | Gemma Ford | Received |
P-154 | Exophiala dermatitidis can undergo patient-patient transmission in cystic fibrosis patients | Jonathan Ayling-Smith | Received |
P-155 | Identification of an evolutionary split in Burkholderia multivorans using phylogenomics: does it have any impacts on the ability to cause cystic fibrosis lung infection? | Kasia Parfitt | Received |
P-156 | Mycobacterium abscessus treatment in adult patients with cystic fibrosis: case series and review | Amel Alameeri | Received |
P-157 | Monitoring the distribution and genotypic diversity of Burkholderiales bacteria in Russian cystic fibrosis patients in the year of the COVID-19 pandemic | Olga Voronina | Received |
P-158 | Fungal airway colonisation in cystic fibrosis patients in the Institute for Respiratory Diseases in Children - Skopje, Republic of North Macedonia | Ivana Arnaudova Danevska | Received |
P-159 | Relationship between clinical and environmental strains of emerging opportunistic pathogens in cystic fibrosis and diversity in the home environment | Quentin Menetrey | Received |
P-160 | Detection and management of non-tuberculous mycobacteria in cystic fibrosis patients in a tertiary paediatric centre | Harriet Wayman | Received |
P-162 | Pneumococcal and influenza vaccination coverage level: data from a cystic fibrosis centre | Elpis Hatziagorou | Received |
P-163 | Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany | Daniela Dolce | Received |
P-164 | What is the tolerance of antibiotic dry powder inhalers in patients with cystic fibrosis? | Paul Wilson | Received |
P-165 | Improvement in antibiotic usage and ppFEV1 with compassionate use of elexacaftor, tezacaftor and ivacaftor (ETI) for patients with cystic fibrosis | Olivia Baker | Received |
P-166 | Prevalence of cystic fibrosis-associated liver disease in Albanian cystic fibrosis patients | Irena Kasmi | Received |
P-167 | Prevalence of liver disease in cystic fibrosis patients in the Institute for Respiratory Diseases in Children - Skopje, Republic of North Macedonia | Ivana Arnaudova Danevska | Received |
P-168 | Use of faecal elastase in patients with cystic fibrosis and mutation analysis in the Republic of North Macedonia | Tatjana Jakovska Maretti | Received |
P-169 | Trends in Glycaemic Control in a Cohort of Patients with Cystic Fibrosis Related Diabetes | Rahana Khanam | Received |
P-170 | Current status of cystic fibrosis-related diabetes in the Bulgarian cystic fibrosis population | GUERGANA PETROVA | Received |
P-171 | Adult cystic fibrosis diabetes patient education and care needs: have your say - a patient survey | Katrin Kosbab-Jackson | Received |
P-172 | Patient experience of Manchester Virtual Cystic Fibrosis-Related Diabetes Clinic during the COVID-19 pandemic | Amanda Brennan | Received |
P-173 | Investigation of cyproheptadine as an appetite stimulator in 6 children with cystic fibrosis with a suboptimal nutritional status | Sara Van Meerbeeck | Received |
P-174 | The association between body composition and respiratory outcomes for patients with cystic fibrosis | Lidia Sheibani | Received |
P-175 | Nutritional status, lung function and adequacy of micronutrient supplementation in children with cystic fibrosis | Tena Niseteo | Received |
P-176 | The benefits of changing to a cystic fibrosis-specific combined fat-soluble vitamin supplement: vitamin status, tablet burden and adherence | Katie Marsden | Received |
P-177 | A review of vitamin levels in children with cystic fibrosis following the introduction of a multi-vitamin preparation | harriet gledhill | Received |
P-180 | Food access challenges and social needs for people with cystic fibrosis | Cristen Clemm | Received |
P-181 | Nutrition support at an adult cystic fibrosis centre | Mandisa Mitchell-Whyte | Received |
P-182 | Developing a model for self-care support of diet and the gut in the routine care of children with cystic fibrosis: a qualitative study | Laurie Cave | Received |
P-183 | The role of the nutritionist in care of adult patients with cystic fibrosis in Republic of North Macedonia | Sonja Panovska | Received |
P-184 | Going green: patient awareness of inhaler indication, usage and environmental impact | Kizzy Snow | Received |
P-185 | Health literacy in children with cystic fibrosis | Cherie Millar | Received |
P-186 | The use of Recombinant human DNase in a large adult cystic fibrosis centre: a quality improvement review | Alison Orr | Received |
P-187 | Measuring the effect of airway clearance in adults with cystic fibrosis a systematic review | Gemma Stanford | Received |
P-188 | Non-invasive ventilation use and management of adult cystic fibrosis patients at end of life | Lucy E Wadsworth | Received |
P-189 | Impact of triple CFTR modulation therapy on non-invasive ventilation use in adults with cystic fibrosis | Lucy E Wadsworth | Received |
P-190 | Adherence 50 to prescribed nebulisers in children with cystic fibrosis is associated with increased hospital admissions and lower FEV1 Z-Score | Kieren James Lock | Received |
P-191 | The use of technology and web-based exercise programmes to improve engagement and quality of exercise sessions delivered to paediatric inpatients during an admission | Louisa Wallbridge | Received |
P-192 | The introduction of a quality improvement focus group in a large UK adult cystic fibrosis centre | Jocelyn Choyce | Received |
P-193 | Audit of cough swab sampling techniques in children with cystic fibrosis | Zoe Johnstone | Received |
P-194 | Implementation of a cystic fibrosis-specific virtual pulmonary rehab program | Catherine Fordyce | Received |
P-195 | Using remote access musculoskeletal consultations within a cystic fibrosis specialist physiotherapy service: a pilot | Becky Dunphy | Received |
P-196 | Evaluation of the efficiency of Frequencer and Vest airways clearance devices in adult cystic fibrotic patients | Peter Borka | Received |
P-197 | Dysglycaemia and changes in aerobic function in cystic fibrosis | Owen Tomlinson | Received |
P-198 | Physical activity is associated with aerobic capacity and lung function in adults with cystic fibrosis | Maire Curran | Received |
P-199 | Assessing the effectiveness of a six-month partially supervised outpatient exercise programme for adults with cystic fibrosis: a service evaluation | Ann Banks | Received |
P-200 | Supporting exercise services in cystic fibrosis: five years of the UK CF & Exercise Network | Owen Tomlinson | Received |
P-201 | The effectiveness of exercise interventions to increase physical activity in cystic fibrosis: a systematic review | Maire Curran | Received |
P-202 | The evaluation of sinonasal and health symptoms in children with cystic fibrosis on Orkambi or Symkevi using the SNOT-22 | Gemma Murray | Received |
P-203 | Fertile ground: pregnancies in a post-Kaftrio pandemic era | Aoife Lillis | Received |
P-204 | The what-ifs....considering the psychological impacts of CFTR modulators | Michele Puckey | Received |
P-205 | Patient-reported outcome measures in the current context of new generation modulator therapies in cystic fibrosis | Kate Hayes | Received |
P-206 | Patient feedback following the introduction of a dedicated Symkevi Initiation Clinic prior to starting modulator therapy | Lynette Haigh | Received |
P-207 | Depression and inflammation in people with cystic fibrosis: a pilot study | Fabiana Ciciriello | Received |
P-208 | Anxiety, depression and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers | Marieke Verkleij | Received |
P-209 | Key priorities in mental health research: results of a community and provider survey across the US | Beth Smith | Received |
P-210 | COACH project - screening for psychological comorbidity in adolescents with cystic fibrosis | Svenja Temming | Received |
P-211 | Use of telemedicine for mental health screening during the COVID-19 pandemic | Heather Bruschwein | Received |
P-212 | Understanding (the experiences of) how mindfulness is used by people with cystic fibrosis: barriers and enablers | Sophia Kauser | Received |
P-213 | Can we attend anywhere? Evaluation of multi-disciplinary team (MDT) remote consultations | Lisa Morrison | Received |
P-214 | Virtual cystic fibrosis doctor: design, development, and user experience pilot study | David Morrissy | Received |
P-215 | Contrasting patient and paediatric cystic fibrosis team perception of telemedicine consultations | Ema Kavaliunaite | Received |
P-217 | Delivering quality improvement coaching in a virtual world: the use of digital technology to empower and engage CFDigiCare clinicians to undertake quality improvement activities nationally | Charlotte Carolan | Received |
P-218 | Detection of anxiety and depression through mental health screening questionnaires in cystic fibrosis patients and their families during the COVID-19 pandemic | Ana Morales Tirado | Received |
P-219 | Before and during the COVID-19 pandemic: a review of health of our paediatric cystic fibrosis patients | Lois Powell | Received |
P-220 | Experiences of virtual cystic fibrosis clinics during the Covid-19 pandemic at one UK adult cystic fibrosis centre | Louise Warnock | Received |
P-221 | Quality of life in adult and children with cystic fibrosis during the COVID-19 pandemic in Croatia | Tihana Odobasic Palkovic | Received |
P-222 | Supporting children with cystic fibrosis: building social networks through the pandemic | Ellie Mindel | Received |
P-223 | The role of psychologist in a cystic fibrosis centre during the COVID-19 pandemic experience of a Polish paediatric centre | Urszula Borawska-Kowalczyk | Received |
P-224 | Change in care during the COVID-19 pandemic: single-centre experience in a middle-income setting | Ilektra Toulia | Received |
P-225 | Parents feedback on virtual paediatric cystic fibrosis clinics during Covid-19 pandemic | Rachel Evans | Received |
P-226 | A survey of family experience of cystic fibrosis care during the COVID-19 pandemic | Jill Watkinson | Received |
P-227 | Cystic fibrosis social workers experience of working during COVID-19 | Fiona Dowdall | Received |
P-228 | Concerns for people with cystic fibrosis when travelling pre-COVID-19 | Cherie Millar | Received |
P-229 | Children and young people with cystic fibrosis enhanced multi-disciplinary pathways to address their educational needs during the evolving COVID-19 pandemic | Chandran Suja | Received |
P-230 | A review of paediatric cystic fibrosis care during the COVID-19 pandemic | Lois Powell | Received |
P-231 | Patient experience of accessing a virtual cystic fibrosis service during the 2020 SARS-CoV-2 pandemic in Blackpool, North West of England | Tarek Saba | Received |
P-232 | The impact of COVID-19 on the relationships between parents of young people diagnosed with cystic fibrosis and the cystic fibrosis multidisciplinary team | Steve Jones | Received |
P-233 | Treatment outcome preferences among people with cystic fibrosis: a discrete choice experiment | Rory Cameron | Received |
P-234 | CFHealthHub a digital learning health system supporting virtual clinics and self-care across 60 of UK adult CF centres: a survey to understand benefits amongst the national CFDigiCare community | Josie Cunningham | Received |
P-235 | Using a 1,500-patient learning health system (LHS) to support virtual clinics and medicines optimisation: a UK seven-centre Patient and Public Involvement (PPI) project to understand user experience | Sophie Dawson | Received |
P-236 | Quantifying the under-served or hard to reach but reachable people with cystic fibrosis (CF) in two UK adult CF centres | Sophie Dawson | Received |
P-237 | The role of beliefs in predicting adherence to nebulised medications in adolescents with cystic fibrosis | Bronwyn Stirzaker | Received |
P-238 | EMBRACEing Medicines Optimisation: working collaboratively to identify barriers and share solutions in the medication pathway across 12 sites within the CFHealthHub | Charlotte Carolan | Received |
P-239 | Pulmonary medication adherence among children and adults with cystic fibrosis | Elpis Hatziagorou | Received |
P-240 | Improving the accuracy of nebulizer prescriptions (and update where necessary) during the medication reconciliation process on CFHealthHub (within 24-hours) | Rianna White | Received |
P-241 | Middle-aged cystic fibrosis patients experiences of living with cystic fibrosis: a qualitative study | Lena Backstrm Eriksson | Received |
P-242 | Ageing with cystic fibrosis: how do older adults with cystic fibrosis adapt to change? | Steven Stirk | Received |
P-243 | The psychological impact of the late diagnosis of atypical cystic fibrosis patients | Guergana Petrova | Received |
P-244 | Moving from paediatric to adult care: resources to support transition | Jacqueline Ali | Received |
P-246 | Transition in cystic fibrosis: international trends | Daniel Office | Received |
P-247 | Improved quality of care increases lung function and growth parameters in children with cystic fibrosis | Fabien Beaufils | Received |
P-248 | Patient Science: a new citizen science approach for health and medical research involving people affected by cystic fibrosis | Johanna Gardecki | Received |
P-249 | Mens health in cystic fibrosis in the modern era: a qualitative study | Traci Kazmerski | Received |
P-250 | Correlation between care allowance levels and antibiotic treatment at the Stockholm Cystic Fibrosis Centre | Eleonora Falk | Received |
P-251 | The experience of adults with cystic fibrosis engaging in a complex health management regime: a meta-ethnography | Steven Stirk | Received |
P-252 | Evaluation of a dashboard-style 1-page coloured CF annual review summary as a novel feedback method to improve communication with families and aid MDT working. | Alison Coates | Received |
P-253 | Share the Sunshine to Improve Staff Wellbeing | Sarah Simmons | Received |
P-254 | Development of a primary palliative care model that includes a novel approach to address the needs of caregivers of adults with cystic fibrosis - improving life with cystic fibrosis: a primary palliative care partnership | Anna Georgiopoulos | Received |
P-255 | Parenthood experience of cystic fibrosis patients and their spouses - An explorative study | Anne Jacob | Received |
P-256 | Waiting for double lung transplantation: psychological impact (review) | Trudy Havermans | Received |
P-257 | Directions of psychological and pedagogical support of children with cystic fibrosis | Sviridova Tatiana | Received |
P-258 | Integrating a diabetes service within the Adult Cystic Fibrosis Service at Blackpool Victoria Hospital, UK | Julie Knowles | Received |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|